Counteracting effects of cellular notch and Epstein-Barr virus EBNA2: Implications for stromal effects on Virus-Host interactions

Journal of Virology

Volumn 88, Issue 20, 2014, Pages 12065-12076

  Rowe, Martin ^a   Raithatha, Sweta ^a   Shannon Lowe, Claire ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN 2; IMMEDIATE EARLY PROTEIN BZLF1; LATENT MEMBRANE PROTEIN 1; NOTCH RECEPTOR; NOTCH2 RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ZEB2; UNCLASSIFIED DRUG; BZLF1 PROTEIN, HERPESVIRUS 4, HUMAN; EBNA-2 PROTEIN, HUMAN HERPESVIRUS 4; EPSTEIN BARR VIRUS ANTIGEN; HOMEODOMAIN PROTEIN; PRIMER DNA; REPRESSOR PROTEIN; TRANSACTIVATOR PROTEIN; VIRUS PROTEIN; ZEB2 PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOBLASTOID CELL LINE; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; STROMA; TRANSCRIPTION INITIATION; UPREGULATION; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS INHIBITION; VIRUS LATENCY; ANIMAL; CELL CULTURE; CELL LINE; GENE EXPRESSION REGULATION; GENETICS; HOST PATHOGEN INTERACTION; METABOLISM; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; POLYMERASE CHAIN REACTION;

ANIMALS; BASE SEQUENCE; CELL LINE; CELLS, CULTURED; DNA PRIMERS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 4, HUMAN; HOMEODOMAIN PROTEINS; HOST-PATHOGEN INTERACTIONS; HUMANS; MICE; POLYMERASE CHAIN REACTION; RECEPTORS, NOTCH; REPRESSOR PROTEINS; TRANS-ACTIVATORS; VIRAL PROTEINS;

EID: 84907908441     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01431-14     Document Type: Article

References (61)

1. Kopan R, Ilagan MX. 2009. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137:216-233. http://dx.doi.org /10.1016/j.cell.2009.03.045.
2. Brou C, Logeat F, Gupta N, Bessia C, LeBail O, Doedens JR, Cumano A, Roux P, Black RA, Israel A. 2000. A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrinmetalloprotease TACE. Mol. Cell 5:207-216. http://dx.doi.org/10.1016/S1097-2765(00)80417-7.
3. Mumm JS, Schroeter EH, Saxena MT, Griesemer A, Tian X, Pan DJ, Ray WJ, Kopan R. 2000. A ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch1. Mol. Cell 5:197-206. http://dx.doi.org/10.1016/S1097-2765(00)80416-5.
4. Kopan R, Schroeter EH, Weintraub H, Nye JS. 1996. Signal transduction by activated mNotch: importance of proteolytic processing and its regulation by the extracellular domain. Proc. Natl. Acad. Sci. U. S. A. 93:1683-1688. http://dx.doi.org/10.1073/pnas.93.4.1683.
5. Struhl G, Adachi A. 1998. Nuclear access and action of notch in vivo. Cell 93:649-660. http://dx.doi.org/10.1016/S0092-8674(00)81193-9.
6. Tamura K, Taniguchi Y, Minoguchi S, Sakai T, Tun T, Furukawa T, Honjo T. 1995. Physical interaction between a novel domain of the receptor Notch and the transcription factor RBP-J kappa/Su(H). Curr. Biol. 5:1416-1423. http://dx.doi.org/10.1016/S0960-9822(95)00279-X.
7. Awong G, La Motte-Mohs RN, Zuniga-Pflucker JC. 2008. In vitro human T cell development directed by Notch-ligand interactions. Methods Mol. Biol. 430:135-142. http://dx.doi.org/10.1007/978-1-59745-182-6_9.
8. Maillard I, Fang T, Pear WS. 2005. Regulation of lymphoid development, differentiation, and function by the Notch pathway. Annu. Rev. Immunol. 23:945-974. http://dx.doi.org/10.1146/annurev.immunol.23.021704.115747.
9. Hozumi K, Negishi N, Suzuki D, Abe N, Sotomaru Y, Tamaoki N, Mailhos C, Ish-Horowicz D, Habu S, Owen MJ. 2004. Delta-like 1 is necessary for the generation of marginal zone B cells but not T cells in vivo. Nat. Immunol. 5:638-644. http://dx.doi.org/10.1038/ni1075.
10. Saito T, Chiba S, Ichikawa M, Kunisato A, Asai T, Shimizu K, Yamaguchi T, Yamamoto G, Seo S, Kumano K, Nakagami-Yamaguchi E, Hamada Y, Aizawa S, Hirai H. 2003. Notch2 is preferentially expressed in mature B cells and indispensable for marginal zone B lineage development. Immunity 18:675-685. http://dx.doi.org /10.1016/S1074-7613(03)00111-0.
11. Tanigaki K, Han H, Yamamoto N, Tashiro K, Ikegawa M, Kuroda K, Suzuki A, Nakano T, Honjo T. 2002. Notch-RBP-J signaling is involved in cell fate determination of marginal zone B cells. Nat. Immunol. 3:443-450. http://dx.doi.org/10.1038/ni793.
12. Thomas M, Calamito M, Srivastava B, Maillard I, Pear WS, Allman D. 2007. Notch activity synergizes with B-cell-receptor and CD40 signaling to enhance B-cell activation. Blood 109:3342-3350. http://dx.doi.org/10.1182/blood-2006-09-046698.
13. Thorley-Lawson DA, Hawkins JB, Tracy SI, Shapiro M. 2013. The pathogenesis of Epstein-Barr virus persistent infection. Curr. Opin. Virol. 3:227-232. http://dx.doi.org/10.1016/j.coviro.2013.04.005.
14. Tierney RJ, Steven N, Young LS, Rickinson AB. 1994. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J. Virol. 68:7374-7385.
15. Zimber-Strobl U, Kremmer E, Grasser F, Marschall G, Laux G, Bornkamm GW. 1993. The Epstein-Barr virus nuclear antigen 2 interacts with an EBNA2 responsive cis-element of the terminal protein 1 gene promoter. EMBO J. 12:167-175.
16. Zimber-Strobl U, Suentzenich KO, Laux G, Eick D, Cordier M, Calender A, Billaud M, Lenoir GM, Bornkamm GW. 1991. Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene. J. Virol. 65:415-423.
17. Sung NS, Kenney S, Gutsch D, Pagano JS. 1991. EBNA-2 transactivates a lymphoid-specific enhancer in the BamHI C promoter of Epstein-Barr virus. J. Virol. 65:2164-2169.
18. Woisetschlaeger M, Jin XW, Yandava CN, Furmanski LA, Strominger JL, Speck SH. 1991. Role for the Epstein-Barr virus nuclear antigen 2 in viral promoter switching during initial stages of infection. Proc. Natl. Acad. Sci. U. S. A. 88:3942-3946. http://dx.doi.org/10.1073/pnas.88.9.3942.
19. Grossman SR, Johannsen E, Tong X, Yalamanchili R, Kieff E. 1994. The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the J kappa recombination signal binding protein. Proc. Natl. Acad. Sci. U. S. A. 91:7568-7572. http://dx.doi.org/10.1073/pnas.91.16.7568.
20. Yalamanchili R, Tong X, Grossman S, Johannsen E, Mosialos G, Kieff E. 1994. Genetic and biochemical evidence that EBNA 2 interaction with a 63-kDa cellular GTG-binding protein is essential for B lymphocyte growth transformation by EBV. Virology 204:634-641. http://dx.doi.org /10.1006/viro.1994.1578.
21. Zimber-Strobl U, Strobl LJ, Meitinger C, Hinrichs R, Sakai T, Furukawa T, Honjo T, Bornkamm GW. 1994. Epstein-Barr virus nuclear antigen 2 exerts its transactivating function through interaction with recombination signal binding protein RBP-J kappa, the homologue of Drosophila Suppressor of Hairless. EMBO J. 13:4973-4982.
22. Henkel T, Ling PD, Hayward SD, Peterson MG. 1994. Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signalbinding protein J kappa. Science 265:92-95. http://dx.doi.org/10.1126 /science.8016657.
23. Hofelmayr H, Strobl LJ, Marschall G, Bornkamm GW, Zimber-Strobl U. 2001. Activated Notch1 can transiently substitute for EBNA2 in the maintenance of proliferation of LMP1-expressing immortalized B cells. J. Virol. 75:2033-2040. http://dx.doi.org/10.1128/JVI.75.5.2033-2040.2001.
24. Sakai T, Taniguchi Y, Tamura K, Minoguchi S, Fukuhara T, Strobl LJ, Zimber-Strobl U, Bornkamm GW, Honjo T. 1998. Functional replacement of the intracellular region of the Notch1 receptor by Epstein-Barr virus nuclear antigen 2. J. Virol. 72:6034-6039.
25. Strobl LJ, Hofelmayr H, Marschall G, Brielmeier M, Bornkamm GW, Zimber-Strobl U. 2000. Activated Notch1 modulates gene expression in B cells similarly to Epstein-Barr viral nuclear antigen 2. J. Virol. 74:1727-1735. http://dx.doi.org/10.1128/JVI.74.4.1727-1735.2000.
26. Kohlhof H, Hampel F, Hoffmann R, Burtscher H, Weidle UH, Holzel M, Eick D, Zimber-Strobl U, Strobl LJ. 2009. Notch1, Notch2, and Epstein-Barr virus-encoded nuclear antigen 2 signaling differentially affects proliferation and survival of Epstein-Barr virus-infected B cells. Blood 113:5506-5515. http://dx.doi.org/10.1182/blood-2008-11-190090.
27. Shannon-Lowe CD, Neuhierl B, Baldwin G, Rickinson AB, Delecluse HJ. 2006. Resting B cells as a transfer vehicle for Epstein-Barr virus infection of epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 103:7065-7070. http: //dx.doi.org/10.1073/pnas.0510512103.
28. Shimizu N, Yoshiyama H, Takada K. 1996. Clonal propagation of Epstein-Barr virus (EBV) recombinants in EBV-negative Akata cells. J. Virol. 70:7260-7263.
29. Delecluse HJ, Hilsendegen T, Pich D, Zeidler R, Hammerschmidt W. 1998. Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. Proc. Natl. Acad. Sci. U. S. A. 95:8245-8250. http://dx.doi.org/10.1073/pnas.95.14.8245.
30. Shannon-Lowe C, Adland E, Bell AI, Delecluse HJ, Rickinson AB, Rowe M. 2009. Features distinguishing Epstein-Barr virus infections of epithelial cells and B cells: viral genome expression, genome maintenance, and genome amplification. J. Virol. 83:7749-7760. http://dx.doi.org/10.1128 /JVI.00108-09.
31. Bell AI, Groves K, Kelly GL, Croom-Carter D, Hui E, Chan AT, Rickinson AB. 2006. Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays. J. Gen. Virol. 87:2885-2890. http://dx.doi.org/10.1099/vir.0.81906-0.
32. Young LS, Lau R, Rowe M, Niedobitek G, Packham G, Shanahan F, Rowe DT, Greenspan D, Greenspan JS, Rickinson AB. 1991. Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia. J. Virol. 65:2868-2874.
33. Young L, Alfieri C, Hennessy K, Evans H, O'Hara C, Anderson KC, Ritz J, Shapiro RS, Rickinson A, Kieff E, Cohen JI. 1989. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N. Engl. J. Med. 321:1080-1085. http://dx.doi.org/10.1056/NEJM198910193211604.
34. Rowe M, Evans HS, Young LS, Hennessy K, Kieff E, Rickinson AB. 1987. Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells. J. Gen. Virol. 68(Pt 6):1575-1586. http://dx.doi.org/10.1099/0022-1317-68-6-1575.
35. Hoffman GJ, Lazarowitz SG, Hayward SD. 1980. Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. Proc. Natl. Acad. Sci. U. S. A. 77:2979-2983. http://dx.doi.org/10.1073/pnas.77.5.2979.
36. Stam NJ, Spits H, Ploegh HL. 1986. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J. Immunol. 137:2299-2306.
37. Ellis-Connell AL, Iempridee T, Xu I, Mertz JE. 2010. Cellular microRNAs 200b and 429 regulate the Epstein-Barr virus switch between latency and lytic replication. J. Virol. 84:10329-10343. http://dx.doi.org /10.1128/JVI.00923-10.
38. Robinson AR, Kwek SS, Hagemeier SR, Wille CK, Kenney SC. 2011. Cellular transcription factor Oct-1 interacts with the Epstein-Barr virus BRLF1 protein to promote disruption of viral latency. J. Virol. 85:8940-8953. http://dx.doi.org/10.1128/JVI.00569-11.
39. Robinson AR, Kwek SS, Kenney SC. 2012. The B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1. PLoS Pathog. 8:e1002516. http://dx.doi.org/10.1371/journal.ppat.1002516.
40. Ellis AL, Wang Z, Yu X, Mertz JE. 2010. Either ZEB1 or ZEB2/SIP1 can play a central role in regulating the Epstein-Barr virus latent-lytic switch in a cell-type-specific manner. J. Virol. 84:6139-6152. http://dx.doi.org/10.1128/JVI.02706-09.
41. Kis LL, Takahara M, Nagy N, Klein G, Klein E. 2006. IL-10 can induce the expression of EBV-encoded latent membrane protein-1 (LMP-1) in the absence of EBNA-2 in B lymphocytes and in Burkitt lymphoma-and NKlymphoma-derived cell lines. Blood 107:2928-2935. http://dx.doi.org /10.1182/blood-2005-06-2569.
42. Kis LL, Gerasimcik N, Salamon D, Persson EK, Nagy N, Klein G, Severinson E, Klein E. 2011. STAT6 signaling pathway activated by the cytokines IL-4 and IL-13 induces expression of the Epstein-Barr virusencoded protein LMP-1 in absence of EBNA-2: implications for the type II EBV latent gene expression in Hodgkin lymphoma. Blood 117:165-174. http://dx.doi.org/10.1182/blood-2010-01-265272.
43. Kis LL, Salamon D, Persson EK, Nagy N, Scheeren FA, Spits H, Klein G, Klein E. 2010. IL-21 imposes a type II EBV gene expression on type III and type I B cells by the repression of C-and activation of LMP-1-promoter. Proc. Natl. Acad. Sci. U. S. A. 107:872-877. http://dx.doi.org /10.1073/pnas.0912920107.
44. + T cells modulate EBV latency. Proc. Natl. Acad. Sci. U. S. A. 109:1512-1517. http://dx.doi.org/10.1073/pnas.1120587109.
45. Ramasubramanyan S, Kanhere A, Osborn K, Flower K, Jenner RG, Sinclair AJ. 2012. Genome-wide analyses of Zta binding to the Epstein-Barr virus genome reveals interactions in both early and late lytic cycles and an epigenetic switch leading to an altered binding profile. J. Virol. 86:12494-12502. http://dx.doi.org/10.1128/JVI.01705-12.
46. Kraus RJ, Perrigoue JG, Mertz JE. 2003. ZEB negatively regulates the lytic-switch BZLF1 gene promoter of Epstein-Barr virus. J. Virol. 77:199-207. http://dx.doi.org/10.1128/JVI.77.1.199-207.2003.
47. Yu X, Wang Z, Mertz JE. 2007. ZEB1 regulates the latent-lytic switch in infection by Epstein-Barr virus. PLoS Pathog. 3:e194. http://dx.doi.org/10.1371/journal.ppat.0030194.
48. Feng WH, Kraus RJ, Dickerson SJ, Lim HJ, Jones RJ, Yu X, Mertz JE, Kenney SC. 2007. ZEB1 and c-Jun levels contribute to the establishment of highly lytic Epstein-Barr virus infection in gastric AGS cells. J. Virol. 81:10113-10122. http://dx.doi.org/10.1128/JVI.00692-07.
49. Persson LM, Wilson AC. 2010. Wide-scale use of Notch signaling factor CSL/RBP-Jkappa in RTA-mediated activation of Kaposi's sarcomaassociated herpesvirus lytic genes. J. Virol. 84:1334-1347. http://dx.doi.org/10.1128/JVI.01301-09.
50. Liang Y, Chang J, Lynch SJ, Lukac DM, Ganem D. 2002. The lytic switch protein of KSHV activates gene expression via functional interaction with RBP-Jkappa (CSL), the target of the Notch signaling pathway. Genes Dev. 16:1977-1989. http://dx.doi.org/10.1101/gad.996502.
51. Wang SE, Wu FY, Yu Y, Hayward GS. 2003. CCAAT/enhancer-binding protein-alpha is induced during the early stages of Kaposi's sarcomaassociated herpesvirus (KSHV) lytic cycle reactivation and together with the KSHV replication and transcription activator (RTA) cooperatively stimulates the viral RTA, MTA, and PAN promoters. J. Virol. 77:9590-9612. http://dx.doi.org/10.1128/JVI.77.17.9590-9612.2003.
52. Wang SE, Wu FY, Fujimuro M, Zong J, Hayward SD, Hayward GS. 2003. Role of CCAAT/enhancer-binding protein alpha (C/EBPalpha) in activation of the Kaposi's sarcoma-associated herpesvirus (KSHV) lyticcycle replication-associated protein (RAP) promoter in cooperation with theKSHVreplication and transcription activator (RTA) and RAP. J. Virol. 77:600-623. http://dx.doi.org/10.1128/JVI.77.1.600-623.2003.
53. Sakakibara S, Ueda K, Chen J, Okuno T, Yamanishi K. 2001. Octamerbinding sequence is a key element for the autoregulation of Kaposi's sarcoma-associated herpesvirus ORF50/Lyta gene expression. J. Virol. 75: 6894-6900. http://dx.doi.org/10.1128/JVI.75.15.6894-6900.2001.
54. Wang SE, Wu FY, Chen H, Shamay M, Zheng Q, Hayward GS. 2004. Early activation of the Kaposi's sarcoma-associated herpesvirus RTA, RAP, and MTA promoters by the tetradecanoyl phorbol acetate-induced AP1 pathway. J. Virol. 78:4248-4267. http://dx.doi.org/10.1128/JVI.78.8.4248-4267.2004.
55. Chang H, Dittmer DP, Shin YC, Hong Y, Jung JU. 2005. Role of Notch signal transduction in Kaposi's sarcoma-associated herpesvirus gene expression. J. Virol. 79:14371-14382. http://dx.doi.org/10.1128/JVI.79.22.14371-14382.2005.
56. Ghosh D, Kieff E. 1990. cis-Acting regulatory elements near the Epstein-Barr virus latent-infection membrane protein transcriptional start site. J. Virol. 64:1855-1858.
57. Anderson LJ, Longnecker R. 2008. An auto-regulatory loop for EBV LMP2A involves activation of Notch. Virology 371:257-266. http://dx.doi.org/10.1016/j.virol.2007.10.009.
58. Anderson LJ, Longnecker R. 2009. Epstein-Barr virus latent membrane protein 2A exploits Notch1 to alter B-cell identity in vivo. Blood 113:108-116. http://dx.doi.org/10.1182/blood-2008-06-160937.
59. Portis T, Dyck P, Longnecker R. 2003. Epstein-Barr virus (EBV) LMP2A induces alterations in gene transcription similar to those observed in Reed-Sternberg cells of Hodgkin lymphoma. Blood 102:4166-4178. http: //dx.doi.org/10.1182/blood-2003-04-1018.
60. Hofelmayr H, Strobl LJ, Stein C, Laux G, Marschall G, Bornkamm GW, Zimber-Strobl U. 1999. Activated mouse Notch1 transactivates Epstein-Barr virus nuclear antigen 2-regulated viral promoters. J. Virol. 73:2770-2780.
61. Deacon EM, Pallesen G, Niedobitek G, Crocker J, Brooks L, Rickinson AB, Young LS. 1993. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J. Exp. Med. 177: 339-349. http://dx.doi.org/10.1084/jem.177.2.339.